GTS Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$611K Buy
+3,897
New +$584K 0.01% 628
2026
Q1
Sell
-2,018
Closed -$278K 1728
2025
Q4
$278K Sell
2,018
-10,494
-84% -$1.37M 0.01% 1098
2025
Q3
$1.6M Buy
12,512
+7,390
+144% +$902K 0.06% 263
2025
Q2
$620K Buy
5,122
+913
+22% +$103K 0.03% 563
2025
Q1
$469K Sell
4,209
-5,441
-56% -$579K 0.02% 721
2024
Q4
$939K Buy
9,650
+1,460
+18% +$156K 0.05% 357
2024
Q3
$942K Buy
+8,190
New +$929K ﹤0.01% 2206

Other funds holding NVS

GTS Securities's NVS Position: Q2 2026 in Review

GTS Securities opened a new position in Novartis (NVS) in Q2 2026: 3,897 shares worth $611K. The stake represents 0.01% of the portfolio and ranks #628 among its holdings. This is a return to the name: GTS Securities previously reported a position in NVS as recently as Q4 2025.

GTS Securities first reported a position in NVS in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.6M in Q3 2025. 1,618 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • GTS Securities held 3,897 shares of Novartis worth $611K as of Q2 2026.
  • Novartis was a new GTS Securities position in Q2 2026.
  • Novartis made up 0.01% of GTS Securities's portfolio in Q2 2026, its #628 holding.
  • GTS Securities first reported a position in Novartis in Q3 2024 and has held it in 7 quarters since.
  • GTS Securities's Novartis position peaked at $1.6M in Q3 2025.
  • 1,618 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.